(Circulation. 2000;101:2658.)
© 2000 American Heart Association, Inc.
Basic Science Reports |
Orally Administered Unfractionated Heparin With Carrier Agent Is Therapeutic for Deep Venous Thrombosis
From the Department of Surgery, The Ochsner Medical Institutions, New Orleans, La (M.D.G., K.S., W.C.S., A.L.-B., S.R.M.), and Emisphere Technologies, Tarrytown, NY (R.A.B.).
Correspondence to Samuel R. Money, MD, Department of Surgery, 1516 Jefferson Hwy, New Orleans, LA 70121. E-mail smoney{at}ochsner.org
Background—Orally administered heparin (OHEP) is unreliable because of poor absorption. Sodium N-(8[2-hydroxybenzoyl]amino) caprylate (SNAC) is an amido acid that facilitates the gastrointestinal absorption of heparin. We evaluated the effectiveness of OHEP combined with SNAC (OHEP/SNAC) in the treatment of deep-vein thrombosis (DVT).
Methods and Results—An internal jugular DVT was produced in 54 male Sprague-Dawley rats. Animals were assigned to 6 different groups for 7 days of treatment: untreated control, subcutaneous heparin (SC HEP) (300 U/kg SC TID), SNAC only (300 mg/kg PO TID), OHEP only (30 mg/kg PO TID), low-molecular-weight heparin (LMWH) (enoxaparin 5 mg/kg SC QD), and OHEP/SNAC (30 mg/kg:300 mg/kg PO TID). The activated partial thromboplastin time (aPTT) and anti–factor X (anti-Xa) levels were measured. The incidence of residual DVT after 1 week of treatment was 100% (9 of 9) in the control group versus 10% (1 of 10) in the OHEP/SNAC and 10% (1 of 10) in the LMWH groups (P<0.001). There was also a significant reduction in clot weights between these groups. Compared with controls, there were no significant differences in the residual DVT in the SNAC-only (6 of 6), OHEP-only (9 of 9), or SC HEP (8 of 10) groups. Combination OHEP/SNAC was as effective in the resolution of the clot and reducing clot weight as LMWH. The aPTT levels in the OHEP/SNAC group peaked at 30 minutes and were significantly higher than in all other groups (P<0.01). Anti-Xa levels were elevated at 15 minutes after dosing in the OHEP/SNAC group and remained significantly elevated at 4 hours (P<0.001).
Conclusions—OHEP combined with a novel carrier agent (SNAC) successfully treated DVT in this rat model.
Key Words: thrombosis • veins • heparin
This article has been cited by other articles:
 |
|
 |
|
  Y. Qi, G. Zhao, D. Liu, Z. Shriver, M. Sundaram, S. Sengupta, G. Venkataraman, R. Langer, and R. Sasisekharan Delivery of therapeutic levels of heparin and low-molecular-weight heparin through a pulmonary route PNAS, June 29, 2004; 101(26): 9867 - 9872. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. H. Tonnessen and S. R. Money Low-Molecular-Weight Heparin Versus Coumarin for the Prevention of Recurrent Venous Thromboembolism in Patients With Cancer Perspectives in Vascular Surgery and Endovascular Therapy, June 1, 2004; 16(2): 144 - 146. [Abstract] [PDF]
|
|
|
|
 |
|
 K. M. Greenlee New Oral Anticoagulants Journal of Pharmacy Practice, August 1, 2002; 15(4): 369 - 376. [Abstract] [PDF]
|
|
|
|
 |
|
 F. G.P. Welt, T. C. Woods, and E. R. Edelman Oral Heparin Prevents Neointimal Hyperplasia After Arterial Injury: Inhibitory Potential Depends on Type of Vascular Injury Circulation, December 18, 2001; 104(25): 3121 - 3124. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. S. Sumner Expert Commentary on Wakefield, T.W.: The Safety, Efficacy, and Cost Efficiency of Outpatient Treatment of Acute Deep Venous Thrombosis with Low Molecular Weight Heparin (pp. 19-26) Perspectives in Vascular Surgery and Endovascular Therapy, January 1, 2000; 13(2): 119 - 123. [PDF]
|
|